Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 221 of 6351
-
New Bladder-Sparing combo could change how we treat aggressive bladder cancer
Disease control Recruiting nowThis phase Ib/II trial studies the side effects, best dose, and effectiveness of enfortumab vedotin (EV) in combination with pembrolizumab and radiation therapy for treating patients with muscle invasive bladder cancer. Standard of care treatment for muscle invasive bladder cance…
Phase 1/2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Reading DNA clues: a blood test that could sniff out lung cancer
Diagnosis Recruiting nowThe purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study wi…
Sponsor: University of Maryland, Baltimore • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Could an antiparasitic drug boost radiation against childhood brain tumors?
Disease control Recruiting nowThe goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic ponti…
Phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for tough esophageal cancer: experimental drug takes on chemo in major trial
Disease control Recruiting nowThis study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic the…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Triple attack on pancreatic cancer: heat, chemo, and immunotherapy combined in new trial
Disease control Recruiting nowThe purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPD…
Phase 2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 26, 2026 16:26 UTC
-
New hope for advanced bladder cancer: experimental drug takes on chemo in major trial
Disease control Recruiting nowThis trial is a registered phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic urothelial carcinoma after failure of PD-1/PD-L1 monoclonal antibody and platinum-based chemotherapy.
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
One vitamin a pill before transplant: a new shield against a deadly complication?
Disease control Recruiting nowThe investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.
Phase 2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New shot could tame COPD Flare-Ups in severe patients
Disease control Recruiting nowA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a psychedelic help break the cannabis habit?
Disease control OngoingCannabis is the most commonly used psychoactive substance in Canada (Lowry \& Corsi, 2020). A sub-group of cannabis users develop a condition known as Cannabis Use Disorder (CUD), which is defined as a regular pattern of cannabis use that causes performance difficulty at work, sc…
Phase 2 • Sponsor: McMaster University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill could ease painful skin condition
Disease control OngoingThe purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Engineered immune cells take on autoimmune diseases
Disease control OngoingThis is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jun 26, 2026 13:50 UTC
-
Can a new pill shrink Hard-to-Treat tumors? a trial aims to find out
Disease control Recruiting nowThis Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
Phase 3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could a One-Time immune cell treatment tame severe vasculitis?
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Timing blood thinners after head injury: a delicate balance between bleeding and stroke risk
Disease control Recruiting nowOlder people falling from a standing height is the most common cause of hospital admission for head injury. Up to 1 in 3 patients admitted are taking a tablet medication which thins the blood, known as an oral anticoagulant. This type of medication can increase the likelihood of …
Phase 3 • Sponsor: Walton Centre NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a new targeted drug shrink lung tumors?
Disease control Recruiting nowThis study is an open-label, multicenter Phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in patients with NSCLC.
Phase 2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Booster shot for Moms-to-Be could shield newborns from deadly infections
Vaccine OngoingThe main objective of the study is to evaluate the persistence of the immunoglobulin G (IgG) antibody responses, specific to Alpha-like protein CN (AlpCN), Ribosomal Protein N (RibN), Alpha-like protein 1N (Alp1N), and Alpha-like protein 2 and 3 (Alp2-3N), after a primary vaccina…
Phase 2/3 • Sponsor: Minervax ApS • Aim: Vaccine
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough lymphoma: Two-Drug combo tested in phase 3 trial
Disease control Recruiting nowThe goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubru…
Phase 3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Sound waves plus immunotherapy: a new attack on breast cancer before surgery
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of high-intensity focused ultrasound (HIFU) combined with toripalimab and chemotherapy as neoadjuvant therapy for ER+/HER2- breast cancer.
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a One-Two punch of CAR-T and stem cell transplant beat myeloma early?
Disease control Recruiting nowEvaluate and compare the safety and efficacy of BCMA-CART ± ASCT in the treatment of newly diagnosed multiple myeloma (NDMM) in young patients
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo attack on breast cancer brain metastases: immunotherapy plus chemo and radiation
Disease control Recruiting nowA Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and concurrent or delayed radiotherapy in patients with adva…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC